Events

Meet Cogstate experts at these upcoming industry events around the globe.

Loading Events

« All Events

  • This event has passed.

AAIC 2019

July 14 - July 18

The Alzheimer’s Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that’ll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer’s disease.

Presentations authored by Cogstate scientisits include:

Sunday, July 14th

[podium] Distinct Contributions of Baseline and Longitudinal Amyloid PET Measures to Memory Decline in Cognitively Normal Older Adults

8:40am – 9:00am | Sun, Jul 14 | Concourse Hall 152, F1-03-03

Yen Ying Ying Lim, PhD1; Reisa A Sperling, MD2,3; Philip Insel, MS4,5; Paul Maruff, PhD6; Keith A Johnson, MD2,7 and Elizabeth C Mormino, PhD8, (1)The Florey Institute for Neurosciences, Melbourne, Australia, (2)Massachusetts General Hospital, Boston, MA, USA, (3)Brigham and Women’s Hospital, Boston, MA, USA, (4)Clinical Memory Research Unit, Lund University, Malmö, Sweden, (5)San Francisco Veteran’s Administration Medical Center, San Francisco, CA, USA, (6)Cogstate Ltd., Melbourne, Australia, (7)Brigham and Women’s Hospital, Boston, MA, USA, (8)Stanford University School of Medicine, Palo Alto, CA, USA

 

[podium] Online Study Partner-Reported Subjective Decline Is Associated with β-Amyloid and Clinical Diagnosis

8:40am – 9:00am | Sun, Jul 14 | 515 AB, F1-01-03

Rachel L Nosheny, PhD1,2; Monica R Camacho, BA2; Scott Mackin, PhD3,4,5; Diana Truran-Sacrey3,6; Derek Flenniken, BS2,6; Aaron Ulbricht3,6; Juliet Fockler, BA2; Paul Maruff, PhD7; Gil D. Rabinovici, MD8,9; Keith Fargo, PhD10; Maria C. Carrillo, Ph.D.10 and Michael W. Weiner, MD2,11, (1)University of California, San Francisco Department of Psychiatry, San Francisco, CA, USA, (2)Center for Imaging of Neurodegenerative Diseases, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA, (3)Center for Imaging of Neurodegenerative Diseases, San Francisco Veterans Administration Medical Center, San Francisco, CA, USA, (4)University of California, San Francisco, San Francisco, CA, USA, (5)Mental Health Service, Department of Veterans Affairs Medical Center, San Francisco, CA, USA, (6)NCIRE, San Francisco, CA, USA, (7)Cogstate Ltd., Melbourne, Australia, (8)Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA, (9)University of California San Francisco, San Francisco, CA, USA, (10)Alzheimer’s Association, Chicago, IL, USA, (11)(2) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA

 

[poster] White Matter Hyperintensities, Amyloid-β, and Risk of Cognitive Decline in Healthy Older People

9:30am – 4:15pm  | Sun, Jul 14 |South Hall GH – Los Angeles Convention Center, P1-352

Nawaf Yassi, MBBS, BSc(Med), FRACP, PhD1,2; Christa Dang1; Amir Fazlollahi, PhD3; Ying Xia, PhD3; Rosie Watson, MBBS, FRACP, PhD2; Paul Maruff, PhD1,4; Olivier Salvado, PhD3; Jurgen Fripp, PhD5; Victor L Villemagne, MD1,2,6,7; Christopher C Rowe, MD1,6,7,8,9 and Colin L Masters, MD6,8, (1)The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, (2)The University of Melbourne, Melbourne, Australia, (3)Commonwealth Scientific and Industrial Research Organisation, Brisbane, Australia, (4)Cogstate Ltd., Melbourne, Australia, (5)CSIRO, Brisbane, Australia, (6)AIBL Research Group, Perth and Melbourne, Australia, (7)Austin Health, Melbourne, Australia, (8)University of Melbourne, Melbourne, Australia, (9)The University of Melbourne, Parkville, Australia

 

[poster] Amyloid-β Positivity Moderates the Relationship between Changes in Brain Morphology and Cognition

9:30am – 4:15pm  | Sun, Jul 14 |South Hall GH – Los Angeles Convention Center, P1-352

Christa Dang1,2; Robert H Pietrzak, PhD3; Yen Ying Ying Lim, PhD2; Nawaf Yassi, MBBS, BSc(Med), FRACP, PhD2,4; Martha Hickey, BA (Hons); MSc (Clin Psych); MBChB, FRANZCOG, MD1; Victor L Villemagne, MD1,2,5; Christopher C Rowe, MD2,5; Colin L Masters, MD2; Paul Maruff, PhD2,6 and the AIBL Study, (1)University of Melbourne, Melbourne, Australia, (2)The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, (3)Yale University, New Haven, CT, USA, (4)The University of Melbourne, Melbourne, Australia, (5)Austin Health, Melbourne, Australia, (6)Cogstate Ltd., Melbourne, Australia

 

Monday, July 15th

[podium] Brooklyn Cognitive Impairments in Health Disparities Pilot Study

8:00am – 8:15am | Mon, Jul 15 | Petree Hall C | O2-01-01

Deborah R Gustafson, MS, PhD1,2; Kerry Adler1; Samuel Apple1; Allison Friedlander, LCSW3; Frank Cheng, MBA4; Steven R Levine, MD1; Michael Lucchesi, MD1; Paul Maruff, PhD5,6; Margaret Salmieri, LCSW1; David Stevens, MD1 and Sarah Weingast1, (1)State University of New York Downstate Medical Center, Brooklyn, NY, USA, (2)University of Skövde, Skövde, Sweden, (3)City University of New York – Hunter College, New York City, NY, USA, (4)Cogstate, Ltd, Boston, MA, USA, (5)Cogstate Ltd., Melbourne, Australia, (6)The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia

 

[podium] Clinical Meaningfulness of Short-Term Cognitive Decline on the Preclinical Alzheimer’s Cognitive Composite-5 (PACC-5) in Normal Older Adults with Elevated β-Amyloid

8:00am – 8:20am | Mon, Jul 15 | Concourse Hall 152, F2-03-01

Kate V Papp, PhD1,2,3; Rachel F. Buckley, PhD3; Elizabeth C Mormino, PhD4; Paul Maruff, PhD5,6; Victor L Villemagne, MD6; Colin L Masters, MD7; Keith A Johnson, MD1,2,3; Dorene Rentz, PsyD3; Reisa A Sperling, MD1,2,3,8 and Rebecca Amariglio, PhD1,2,3, (1)Harvard Medical School, Boston, MA, USA, (2)Brigham and Women’s Hospital, Boston, MA, USA, (3)Massachusetts General Hospital, Boston, MA, USA, (4)Stanford University School of Medicine, Palo Alto, CA, USA, (5)Cogstate Ltd., Melbourne, Australia, (6)The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, (7)AIBL Research Group, Perth and Melbourne, Australia, (8)Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

 

Tuesday, July 16th

[podium] Neuropsychology: Neuropsychological Features of the Disease Phases as Defined by the NIA-AA Research Framework

8:00am – 9:30am | Tue, Jul 16 | Petree Hall D, O3-03

Session Chair: Paul Maruff, PhD, The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia and Kimberly D Mueller, MS, PhD, Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

 

[podium] Associations of Subthreshold Amyloid-β Accumulation with Hippocampal Atrophy and Memory Decline

8:15am – 8:30am | Tue, Jul 16 | Petree Hall D, O3-03

Christa Dang1,2; Robert H Pietrzak, PhD3; Yen Ying Ying Lim, PhD1; Nawaf Yassi, MBBS, BSc(Med), FRACP, PhD1,4; Martha Hickey, BA (Hons); MSc (Clin Psych); MBChB, FRANZCOG, MD2; Victor L Villemagne, MD1,2,5; Christopher C Rowe, MD2,5; Colin L Masters, MD1; Paul Maruff, PhD1,6 and the AIBL Study, (1)The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, (2)University of Melbourne, Melbourne, Australia, (3)Yale University, New Haven, CT, USA, (4)The University of Melbourne, Melbourne, Australia, (5)Austin Health, Melbourne, Australia, (6)Cogstate Ltd., Melbourne, Australia

 

[poster] Equivalence of Different Language Versions of the International Shopping List Test in the Phase 3 Mission AD Studies

9:30am – 4:15pm | Tue, Jul 16 | South Hall GH, P3-459

Adrian Schembri, DPsych1Paul Maruff, PhD1,2; Michelle Gee, PhD3 and Bruce Albala, PhD4, (1)Cogstate Ltd., Melbourne, Australia, (2)The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, (3)Eisai, London, United Kingdom, (4)Eisai Inc., Woodcliff Lake, NJ, USA

 

[poster] Clinical Meaningfulness of Short-Term Cognitive Decline on the Preclinical Alzheimer’s Cognitive Composite-5 (PACC-5) in Normal Older Adults with Elevated β-Amyloid

9:30am – 4:15pm | Tue, Jul 16 | South Hall GH, P3-031

Kate V Papp, PhD1,2,3; Rachel F. Buckley, PhD3; Elizabeth C Mormino, PhD4; Paul Maruff, PhD5,6; Victor L Villemagne, MD6; Colin L Masters, MD7; Keith A Johnson, MD3; Dorene M Rentz, PsyD3; Reisa A Sperling, MD2 and Rebecca Amariglio, PhD2,3, (1)Harvard Medical School, Boston, MA, USA, (2)Brigham and Women’s Hospital, Boston, MA, USA, (3)Massachusetts General Hospital, Boston, MA, USA, (4)Stanford University School of Medicine, Palo Alto, CA, USA, (5)Cogstate Ltd., Melbourne, Australia, (6)The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, (7)AIBL Research Group, Perth and Melbourne, Australia

 

[poster] Use of a Modified Hidden Pathway Maze Test in Patients with Alzheimer’S Disease Dementia

9:30am – 4:15pm | Tue, Jul 16 | South Hall GH, P3-025

Chris J. Edgar, PhD1; Tim Tasker2; Adrian Schembri, DPsych3; Babli Millais2; Bharat Ruparelia2; Odile Dewit2; Stephen Jones2; Paul Maruff, PhD3 and Pradeep J Nathan, PhD2, (1)Cogstate Ltd., London, United Kingdom, (2)Sosei Heptares, Cambridge, United Kingdom, (3)Cogstate Ltd., Melbourne, Australia

 

Wednesday, July 17th

[podium] Identifying Elders at risk for Cognitive Decline using the Brain Health Registry (BHR)

8:00am – 8:20am | Wed, Jul 17 | Petree Hall C, S4-01-01

Michael W. Weiner, MD1,2; Rachel L Nosheny, PhD2,3; R Scott Mackin, PhD2,3; Diana Truran-Sacrey2; Derek Flenniken, BS2; Monica R Camacho, BA2; Winnie Kwang, BA2; Taylor Howell, BS2; Juliet Fockler, BA2; Michael L Alosco, PhD4; Robert A Stern, PhD4; Thomas J. Montine, MD, PhD5; Brenna Cholerton, PhD5; J Wesson Ashford, MD, PhD6; Paul Maruff, PhD7 and Cassandra Szoeke, PhD MD FRACP MBBS BSc(Hons)8, (1)(2) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA, (2)Center for Imaging of Neurodegenerative Diseases, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA, (3)University of California, San Francisco Department of Psychiatry, San Francisco, CA, USA, (4)Boston University School of Medicine, Boston, MA, USA, (5)Stanford University Department of Pathology, Stanford, CA, USA, (6)(6) Stanford University Department of Psychiatry and Behavioral Sciences, Stanford, CA, USA, (7)Cogstate Ltd., Melbourne, Australia, (8)Healthy Brain Initiative, Australian Catholic University, Melbourne, Australia

 

[podium] Increasing the Impact of the Ideas Study Using Brain Health Registry Online Data Collection

8:18am – 8:36am | Wed, Jul 17 | 502 AB, F4-01-02

Rachel L Nosheny, PhD1,2Monica R Camacho, BA2,3; Derek Flenniken, BS2,3; Aaron Ulbricht3,4; Juliet Fockler, BA2; Scott Mackin, PhD4,5; Diana Truran-Sacrey2,3; Paul Maruff, PhD6; Gil D. Rabinovici, MD7,8; Keith Fargo, PhD9; Maria C. Carrillo, Ph.D.9 and Michael W. Weiner, MD2,10, (1)University of California, San Francisco Department of Psychiatry, San Francisco, CA, USA, (2)Center for Imaging of Neurodegenerative Diseases, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA, (3)NCIRE, San Francisco, CA, USA, (4)Center for Imaging of Neurodegenerative Diseases, San Francisco Veterans Administration Medical Center, San Francisco, CA, USA, (5)University of California, San Francisco, San Francisco, CA, USA, (6)Cogstate Ltd., Melbourne, Australia, (7)Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA, (8)University of California San Francisco, San Francisco, CA, USA, (9)Alzheimer’s Association, Chicago, IL, USA, (10)(2) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA

 

[poster] SPON1 is associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal adults

9:30am – 4:15pm | Wed, Jul 17 | South Hall GH, P4-485

Tenielle Porter, PhD, BSc (Hons)1; Samantha C Burnham, PhD2; Lidija Milicic, BSc1; Greg Savage, PhD3; Paul Maruff, PhD4; Madeline Peretti, BSc, MSc1; Hamid R Sohrabi, PhD5; Yen Ying Ying Lim, PhD6; Michael Weinborn, PhD5; David Ames, MBBS, MD7; Colin L Masters, MD8; Ralph N Martins, PhD9; Stephanie R Rainey-Smith, PhD9; Christopher Rowe, MD7; Olivier Salvado, PhD10; David Groth, PhD11; Giuseppe Verdile, PhD12; Victor L Villemagne, MD13 and Simon M Laws, PhD14, (1)Edith Cowan University, Joondalup, WA, Australia, (2)CSIRO, Melbourne, Australia, (3)Macquarie University, Sydney, Australia, (4)The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, (5)Australian Alzheimer’s Research Foundation, Perth, Western Australia, Australia, (6)Washington University in St. Louis, St. Louis, MO, USA, (7)The University of Melbourne, Parkville, VIC, Australia, (8)The University of Melbourne, Melbourne, Australia, (9)Edith Cowan University, Joondalup, Western Australia, Australia, (10)CSIRO, Brisbane, Australia, (11)Curtin University, Bentley, WA, Australia, (12)Curtin University, Perth, Australia, (13)Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, Australia, (14)Edith Cowan University, Joondalup, Australia

 

[poster] Data Quality Metrics for Clinical Outcome Assessments in Alzheimer’s Disease Clinical Trials

9:30am – 4:15pm | Wed, Jul 17 | South Hall GH, P4-018

Chris J. Edgar, PhD, Cogstate Ltd., London, United Kingdom; Adrian Schembri, DPsych, Cogstate Ltd., Melbourne, Australia and Edward I. Bartolic, PhD, Cogstate, New Haven, CT, USA

 

[poster] Removing Barriers to Alzheimer’s Disease Clinical Trial Execution: GAP Rater Certification Program

9:30am – 4:15pm | Wed, Jul 17 | South Hall GH, P4-257

Richard Mohs, PhD1; Jason Bork, B.S.1; Katy Smith1; John Dwyer, JD1 and Edward I. Bartolic, PhD2, (1)Global Alzheimer’s Platform (GAP) Foundation, Washington, DC, USA, (2)Cogstate, New Haven, CT, USA

Register

Contact Us

  • This form collects personal information like your name and email so that we can process your contact request. Please review our Privacy Policy for details on how we protect and manage your submitted data.

  • This field is for validation purposes and should be left unchanged.

Details

Start:
July 14
End:
July 18
Website:
https://www.alz.org/aaic/overview.asp